Impact of commercial and autogenous Escherichia coli vaccine combination on broiler breeder stock performance, gross pathology, and diversity of Escherichia coli isolates

Avian colibacillosis is one of the main causes of economic losses in the poultry industry worldwide. Vaccination could help to prevent infection during the laying period on broiler breeder farms. Effective vaccination against avian pathogenic Escherichia coli (APEC) may be an essential step for protection of poultry flocks depending on the region where they are raised. The aim of this study was to investigate the additive protective effect of an autogenous E. coli vaccine in broiler breeders pre-vaccinated with a licensed E. coli vaccine (Poulvac®). Our field study was partially blinded and parallel group designed. Group 1 included 24 000 laying hens vaccinated by Poulvac®. Group 2 comprised 12 000 laying hens vaccinated by Poulvac® and additionally, by an autogenous E. coli vaccine via intramuscular application before transfer. The effectiveness of vaccination in both groups was evaluated according to the results of gross pathology, bacteriology (isolation and characterization of E. coli) and utility indicators. Based on the pathology, the occurrence of E. coli polyserositis syndrome (EPS), salpingoperitonitis syndrom (SPS), and haemorrhagic septicaemia was decreased in Group 2 compared to Group 1. The difference in the occurrence of EPS (P < 0.001) and SPS (P = 0.0342) was significant. The proportion of serotype O78 among E. coli isolated from Group 1 and Group 2 was also significant (P = 0.0178). The effective and multi-serotype vaccination program in order to expand heterologous protection of laying hens and combination of commercial and autogenous vaccines seems to be a promising preventive management tool.